← The Wire
AORTNYSE
ARTIVION, INC.
Surgical & Medical Instruments & Apparatus · DE · CIK 784199
Manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgery
$976M
Market cap
$22.39
Last close
-5.2%
1D
+11.2%
5D
1.0M
Volume
Price · last 39 sessions-37.0%
May 4L $20.10 · H $35.91Jun 29
164
Total filings
May 18, 2026
Last filing
12/31
Fiscal year end
8-KReg FD Disclosure · Company UpdateMay 18, 20268-KShareholder VoteMay 15, 202610-Q10-QMay 8, 20268-KMaterial Agreement · Results of OperationsMay 7, 2026DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSApr 1, 2026DEF 14ADEFINITIVE PROXY STATEMENTApr 1, 202610-K10-KFeb 18, 20268-KResults of OperationsFeb 12, 202610-Q10-QNov 7, 20258-KResults of OperationsNov 6, 20258-KMaterial AgreementSep 29, 20258-KMaterial Agreement · New Debt / ObligationSep 15, 20258-KExecutive ChangeAug 11, 202510-Q10-QAug 8, 20258-KResults of OperationsAug 7, 20258-KEquity Issuance · Company UpdateMay 29, 20258-KShareholder VoteMay 16, 20258-KEquity Issuance · Company UpdateMay 14, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 5, 2025DEFA14AADDITIONAL DEFINITIVE PROXY MATERIALSApr 1, 2025DEF 14ADEFINITIVE PROXY STATEMENTApr 1, 202510-K10-KFeb 28, 20258-KResults of OperationsFeb 24, 20258-KCompany UpdateDec 23, 20248-KCompany UpdateDec 9, 20248-KCompany UpdateDec 9, 202410-Q10-QNov 8, 20248-KResults of OperationsNov 7, 202410-Q10-QAug 9, 20248-KResults of OperationsAug 8, 20248-KMaterial Agreement · Reg FD DisclosureJul 1, 20248-KBylaw AmendmentMay 17, 20248-KBylaw Amendment · Shareholder VoteMay 16, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 6, 2024DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSApr 1, 2024DEF 14ADEFINITIVE PROXY STATEMENTApr 1, 2024SC 13GSC 13GMar 11, 202410-K10-KFeb 23, 20248-KResults of OperationsFeb 15, 20248-KMaterial Agreement · New Debt / ObligationJan 18, 20248-KExecutive Change · Reg FD DisclosureDec 6, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 2, 20238-KBylaw AmendmentAug 8, 202310-Q10-QAug 4, 20238-KResults of OperationsAug 3, 20238-KShareholder VoteMay 19, 202310-Q10-QMay 5, 20238-KResults of OperationsMay 4, 2023DEFA14AADDITIONAL DEFINITVE MATERIALApr 3, 2023DEF 14ADEFINITIVE PROXY STATEMENTApr 3, 202310-K10-KFeb 23, 20238-KResults of OperationsFeb 16, 2023SC 13GMS INITIALFeb 8, 2023SC 13GSEC SCHEDULE 13GFeb 6, 2023SC 13GSC 13GJan 20, 20238-KChange of ControlNov 9, 202210-Q10-QNov 4, 20228-KResults of OperationsNov 3, 20228-KExecutive ChangeSep 29, 2022SC 13DSC 13DSep 26, 20228-KReg FD DisclosureSep 23, 20228-KCode of EthicsAug 5, 202210-Q10-QAug 5, 20228-KResults of OperationsAug 4, 20228-KShareholder VoteMay 20, 202210-Q10-QMay 6, 20228-KResults of OperationsMay 5, 2022DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSApr 4, 2022DEF 14ADEFINITIVE PROXY STATEMENTApr 4, 202210-K10-KFeb 22, 20228-KResults of OperationsFeb 17, 20228-KBylaw Amendment · Company UpdateJan 20, 20228-KSecurity-Holder Rights · Bylaw AmendmentJan 4, 20228-KShareholder VoteNov 18, 202110-Q10-QNov 5, 20218-KResults of OperationsNov 4, 2021DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSOct 7, 2021
Insider Activity
In the 90 days to Mar 4, 2026: 6 sold $5.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Holloway Jean FSVP, General Counsel | Sell | 8,962 | $38.00 | $341K |
| Mar 3, 2026 | Mackin James PPresident & CEO | Sell | 17,887 | $37.78 | $676K |
| Mar 3, 2026 | Berry Lance AEVP, COO, CFO & Treasurer | Sell | 6,316 | $37.78 | $239K |
| Mar 3, 2026 | Davis John EChief Commercial Officer | Sell | 4,573 | $37.78 | $173K |
| Mar 3, 2026 | Holloway Jean FSVP, General Counsel | Sell | 3,843 | $37.78 | $145K |
| Mar 3, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair | Sell | 2,149 | $37.78 | $81K |
| Mar 3, 2026 | Horton AmyVP, Chief Accounting Officer | Sell | 901 | $37.78 | $34K |
| Mar 2, 2026 | Mackin James PPresident & CEO | Sell | 14,911 | $38.02 | $567K |
| Mar 2, 2026 | Berry Lance AEVP, COO, CFO & Treasurer | Sell | 5,178 | $38.02 | $197K |
| Mar 2, 2026 | Davis John EChief Commercial Officer | Sell | 2,784 | $38.02 | $106K |
| Mar 2, 2026 | Holloway Jean FSVP, General Counsel | Sell | 2,183 | $38.02 | $83K |
| Mar 2, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair | Sell | 1,513 | $38.02 | $58K |
| Mar 2, 2026 | Horton AmyVP, Chief Accounting Officer | Sell | 641 | $38.02 | $24K |
| Feb 24, 2026 | Mackin James PPresident & CEO | Sell | 13,936 | $35.69 | $497K |
| Feb 24, 2026 | Berry Lance AEVP, COO, CFO & Treasurer | Sell | 4,485 | $35.69 | $160K |
| Feb 24, 2026 | Davis John EChief Commercial Officer | Sell | 2,075 | $35.69 | $74K |
| Feb 24, 2026 | Holloway Jean FSVP, General Counsel | Sell | 1,668 | $35.69 | $60K |
| Feb 24, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair | Sell | 1,259 | $35.69 | $45K |
| Feb 24, 2026 | Horton AmyVP, Chief Accounting Officer | Sell | 830 | $35.69 | $30K |
| Feb 23, 2026 | Mackin James PPresident & CEO | Sell | 20,962 | $37.59 | $788K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance